Seneca Therapeutics, Inc Biotechnology
11 employees on LinkedIn · 5 known investors
Find your way into Seneca Therapeutics, Inc Biotechnology
92 people in our graph share verified history with the Seneca Therapeutics, Inc Biotechnology team — schools, employers, funds. One of them is your warm intro.
Prashant Shahunlockedknows Paul L. Hallenbeck · together at University of Illinois Urbana-Champaign (overlapped)
×7knows the team · via University of Illinois Urbana-Champaign
×4knows the team · via Siena University
Seneca Therapeutics develops oncolytic virus immunotherapies, particularly Seneca Valley Virus (SVV-001), for treating aggressive and therapy-resistant solid cancers. The company's pipeline includes both monotherapy and gene-armed viral approaches targeting multiple cancer indications, with an IND application open to begin clinical trials in early 2025.
Founders & leadership
PL
Paul L. HallenbeckinFounder, President and Chief Scientific OfficerPaul Hallenbeck is a biotechnology executive with 25 years of experience in oncology drug discovery and development, including work across antibodies, gene therapy, immunotherapy, and oncolytic viruses from candidate selection through clinical trials and regulatory submissions. He has founded and led multiple biotech companies and programs, holds 35+ patents, and has authored over 30 scientific publications.
Investors · 5
Frequently asked questions
- What does Seneca Therapeutics, Inc Biotechnology do?
- Seneca Therapeutics develops oncolytic virus immunotherapies, particularly Seneca Valley Virus (SVV-001), for treating aggressive and therapy-resistant solid cancers. The company's pipeline includes both monotherapy and gene-armed viral approaches targeting multiple cancer indications, with an IND application open to begin clinical trials in early 2025.
- Who founded Seneca Therapeutics, Inc Biotechnology?
- Seneca Therapeutics, Inc Biotechnology was founded by Paul L. Hallenbeck.
- Who are Seneca Therapeutics, Inc Biotechnology's investors?
- Seneca Therapeutics, Inc Biotechnology's investors include Broad Street Angels, Delaware Crossing Investor Group, Dellin Investments, Keiretsu Forum, NW Angel.